Form 4: Cidara Therapeutics Acquired by Merck for $221.50/Share

Cidara Therapeutics, Inc. completed its merger with Merck, with shareholders receiving $221.50 per common share and $15,505.00 per Series A preferred share in cash.

Summary

• The merger of Cidara Therapeutics, Inc. with Caymus Purchaser, Inc., a wholly-owned subsidiary of Merck Sharp & Dohme LLC, was completed on January 7, 2026.
• Common shareholders received $221.50 per share in cash for their tendered shares.
• Series A Convertible Voting Preferred Stock shareholders received $15,505.00 per share in cash for their tendered shares.
• All outstanding stock options became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were cancelled at the effective time of the merger and converted into a cash payment equal to the product of the number of shares subject to the option multiplied by the excess of $221.50 per common share over the option's exercise price.
• Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck.
• A 1-for-20 reverse stock split, effected by Cidara Therapeutics, Inc. on April 24, 2024, adjusted the reported number of securities and exercise prices.

Sentiment

Score: 7

Explanation: The completion of a merger at a pre-agreed price is generally positive for shareholders, providing a definitive cash exit and liquidity. The score reflects the successful execution of a strategic transaction, offering a premium for shares, though it marks the end of the company's independent public life.

Positives

• Shareholders received a definitive cash payment of $221.50 per common share and $15,505.00 per Series A preferred share, providing immediate liquidity.
• Stock options were fully vested and converted into cash payments, allowing option holders to realize value.
• The merger provides a clear exit strategy for investors in Cidara Therapeutics, Inc.

Negatives

• Cidara Therapeutics, Inc. ceased to be an independent publicly traded company.
• Shareholders no longer participate in the potential future growth or independent strategic direction of Cidara Therapeutics, Inc.

Future Outlook

Cidara Therapeutics, Inc. is now a wholly-owned subsidiary of Merck Sharp & Dohme LLC. Its independent future outlook is subsumed within Merck's broader operations and strategic objectives.

Industry Context

This acquisition by Merck reflects a broader industry trend where larger pharmaceutical companies acquire smaller biotechnology firms to enhance their drug pipelines, gain access to innovative technologies, and expand their market presence. Such transactions often provide a strategic exit for biotech investors and integrate specialized expertise into established industry players.

Stakeholder Impact

• Shareholders: Received cash for their shares and options, providing liquidity and a return on investment.
• Employees: Cidara Therapeutics continues as a subsidiary, implying continued employment, though under new ownership (Merck), which may bring new opportunities or changes.
• Customers/Suppliers: Operations are expected to continue under Merck's ownership, potentially benefiting from Merck's resources and scale.

Next Steps

• Cidara Therapeutics, Inc. will operate as a wholly-owned subsidiary of Merck Sharp & Dohme LLC.

Key Dates

Keywords

Cidara Therapeutics, CDTX, Merck, Merger, Acquisition, Tender Offer, Stock Split, Form 4, Biotechnology, Pharmaceuticals